Roivant and Plexcera spin out Farber disease biotech Enzyvant

14 July 2016

Bermuda-based Roivant Sciences and US firm Plexcera Therapeutics have announced the formation of Enzyvant Sciences, a new biopharmaceutical company focused on the development of recombinant human acid ceramidase (rhAC), an enzyme replacement therapy for the treatment of patients with Farber disease.

Developed in the lab of Professor Edward Schuchman, at the Icahn School of Medicine at Mount Sinai, rhAC showed promising results in a mouse model of Farber disease, and was initially licensed to Plexcera prior to the formation of Enzyvant. At Enzyvant, the rhAC program will benefit from the continued involvement of the experienced medical and scientific team from Plexcera, while gaining the extensive pharmaceutical development expertise and financial support of Roivant.

Enzyvant expects to rapidly progress the development of rhAC by:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK